INFOGRAPHICS

Explore our summarised infographics.

Prescribing information for DOVATO (dolutegravir/lamivudine) can be found here.
Prescribing information for VOCABRIA (cabotegravir) + REKAMBYS (rilpivirine) can be found here.

Results:

Showing results for

VOCABRIA + REKAMBYS

Real-World meta-analysis and VOLITION data from EACS 2025

DOVATO

Data from DOLCE and ATTEND from Glasgow 2024

DOVATO

5 Years of Clinical and Real World Evidence Data

VOCABRIA + REKAMBYS

Key SOLAR PRO data

PM-GB-HVX-WCNT-220003 | June 2025

Adverse event reporting

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GSK via the GSK Reporting Tool or on 0800 221441.

If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.